Public support in the United States for global equity in vaccine pricing

[1]  S. Moon,et al.  Averting Future Vaccine Injustice. , 2021, The New England journal of medicine.

[2]  L. C. Wang,et al.  Awareness of ethical dilemmas enhances public support for the principle of saving more lives in the United States: A survey experiment based on ethical allocation of scarce ventilators. , 2021, Social science & medicine.

[3]  R. Malpani,et al.  Suspend intellectual property rights for covid-19 vaccines , 2021, British medical journal.

[4]  Jean‐François Bonnefon,et al.  Public opinion on global rollout of COVID-19 vaccines , 2021, Nature Medicine.

[5]  E. Emanuel,et al.  An ethical framework for global vaccine allocation , 2020, Science.

[6]  Rachel Silverman,et al.  Value-based tiered pricing for universal health coverage: an idea worth revisiting , 2020, Gates open research.

[7]  Feng Zhao,et al.  Ensuring global access to COVID-19 vaccines , 2020, The Lancet.

[8]  John-Arne Røttingen,et al.  Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study , 2018, The Lancet Global Health.

[9]  P. Danzon.  Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues , 2018, PharmacoEconomics.

[10]  S. Plotkin,et al.  The complexity and cost of vaccine manufacturing – An overview , 2017, Vaccine.

[11]  D. Hartman,et al.  Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization , 2016, PloS one.

[12]  P. Hill,et al.  Cautionary Notes on a Global Tiered Pricing Framework for Medicines. , 2015, American journal of public health.

[13]  S. Crager.  Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways. , 2014, American journal of public health.

[14]  M. Balasegaram.  Is tiered pricing the way for vaccines? , 2014, The Lancet.

[15]  S. Berkley.  Improving access to vaccines through tiered pricing , 2014, The Lancet.

[16]  S. Quinn,et al.  US Public Support for Vaccine Donation to Poorer Countries in the 2009 H1N1 Pandemic , 2012, PloS one.

[17]  William W. Fisher,et al.  The Health Crisis in the Developing World and What We Should Do About It , 2012 .

[18]  Michelle L. Childs,et al.  A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries , 2011, Globalization and health.

[19]  William W. Fisher.  1 WHEN SHOULD WE PERMIT DIFFERENTIAL PRICING OF INFORMATION ? , 2007 .

[20]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[21]  M. Kieny,et al.  Assembling a global vaccine development pipeline for infectious diseases in the developing world. , 2006, American Journal of Public Health.

[22]  Julia Fox-Rushby,et al.  Vaccine-preventable Diseases , 2006 .

[23]  Nuno Sousa Pereira,et al.  Vaccine supply: a cross-national perspective. , 2005, Health affairs.

[24]  Jens Plahte.  Tiered pricing of vaccines: a win-win-win situation, not a subsidy. , 2005, The Lancet. Infectious diseases.

[25]  Adrian Towse,et al.  Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents , 2003, International Journal of Health Care Finance and Economics.